Author

R. Correa-Rocha

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:CITE-seq· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

M. Pion· 2 shared A. Bertoletti· 1 shared A. Halpin· 1 shared A. Ortiz· 1 shared B. Motyka· 1 shared C. Berin· 1 shared C. Camara· 1 shared D. Carbonell-Munoz· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

M. Pion

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ABO blood group is involved in the quality of the specific immune response

S. Gil-Manso, I. Miguens Blanco, B. Motyka, A. Halpin, R. Lopez-Estaban, V. A. Perez-Fernandez, D. Carbonell-Munoz, L. A. Lopez-Fernandez, L. J. west, R. Correa-Rocha, M. Pion

The study shows that ABO blood group and age affect the persistence of SARS-CoV-2-specific immune responses, with A-group individuals showing higher CD4+ T-cell responses against M-protein but slower viral clearance.

bioRxiv · May 23, 2021 · PreprintImmunology

Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals

C. Camara, D. Lozano-Ojalvo, E. Lopez-Granados, E. Paz-Artal, M. Pion, R. Correa-Rocha, A. Ortiz, M. Lopez-Hoyos, M. Erro Iribarren, J. Portoles, P. Portoles, M. Perez-Olmeda, J. Oteo-Iglesias, C. Berin, E. Guccione, , J. Ochando

This study examines how the second dose of the BNT162b2 vaccine affects T cell immunity in naive and previously infected individuals, finding reduced cellular immunity in recovered individuals.

bioRxiv · Mar 22, 2021Immunology